Value creation specialist Jayshree (Jay) Shah has joined Interpath to lead the firm’s support for Healthcare & Life Sciences businesses. The announcement comes as the independent, multidisciplinary firm continues to invest in its growing Advisory practice.
Jay arrives at Interpath in London from FTI where she was the EMEA Healthcare & Life Sciences sector lead in the Corporate Finance & Restructuring practice. She has been appointed as a Managing Director at Interpath in its Value Creation team and the firmwide Sector Lead for Healthcare & Life Sciences.
Jay has over 20 years of experience in working with both Corporate and Private Equity clients. Her experience covers a range of advisory services, including value creation, commercial and operational pre-deal diligence, business transformation, accelerated operational cost reduction, carve-outs and post-deal integration.
As well as working for PwC and EY in their operational deal advisory teams, Jay is Association of the British Pharmaceutical industry (ABPI) qualified and has extensive hands-on Pharmaceutical & Healthcare industry experience having spent half her career working in-house in the industry, including roles at Schering Plough (MSD), Datamonitor Pharma and Amdipharm (now Advanz Pharma).
Prior to FTI, Jay was appointed European Strategy Leader at a NASDAQ listed digital interactions company Conduent (formally Xerox), where she was responsible for driving growth in the European footprint through an effective corporate and go-to-market strategy across four key verticals (Pharmaceuticals & Healthcare, Banking & Insurance, TMT and Automotive).
Interpath now employs more than 160 professionals in its Advisory practice, delivering full-service deal advisory, including M&A, transaction services, debt advisory, and M&A tax, as well as forensics, valuations, data analytics, and value creation. The firm advised on more than 130 transactions in 2023.
Interpath has also hired Robbie McFaul as a Director in its Transactions Services team. Robbie arrives after nearly 11 years with PwC where he specialised in transactions within the healthcare, pharmaceutical, technology, media & telecommunications sectors. Based out of Interpath’s Leeds office, Robbie will support Managing Director Louise Smith who joined the firm from EY in October 2023.
Commenting on her appointment, Jay Shah said: “Joining Interpath provides me with an excellent opportunity to pursue my passion and to make a real difference to organisations in the Healthcare and Life sciences sector. I’m able to build a team with autonomy that’s not conflicted and draws on specialists from across its multi-disciplinary capabilities to deliver meaningful value for clients.
“I’m also focused on further expanding our Value Creation team itself as part of Interpath’s thriving Advisory practice. The pressure has never been greater for investors to create value and have impact which puts at the heart of the M&A market as we support across the deal cycle.”
Commenting on his appointment, Robbie McFaul, Transaction Services Director at Interpath in Leeds, said: “I’ve been impressed by the scale that Interpath and its Deal Advisory team have already achieved, but also the thriving entrepreneurial culture and multi-disciplinary model. It is an exciting place to be and the perfect moment to join as we build a proposition that really challenges the market for the benefit of corporates, investors, and business owners. It is a privilege to join Louise and her team and can’t wait to get stuck in at such a critical period in the regional dealmaking market.”
Mark Raddan, Head of Advisory at Interpath, said: “With each appointment, we’re making major strides forward as we build out our Advisory practice. We have market-leading professionals across a full suite of services and these appointments are further evidence of our commitment to invest, bring in the best talent and demonstrates our ambition for further growth.
“Jay is an exceptional talent in the Pharmaceutical and wider Healthcare and Life Sciences industry and will lead our engagement for what is an incredibly important sector for the UK economy and M&A market. With Jay’s extensive transaction and value creation experience, and Robbie’s work over the past decade in transaction services, we’re adding even more depth to our already thriving advisory offering.”
